Ian Harnett, a European analyst at Absolute Strategy Research, believes stocks will rally another 20 percent in 2014.» Read More
What a week on "Squawk Box"! Bill Ackman teams up with Valeant to buy Botox-maker Allergan. Novartis' buying and selling and lil' Squawkers running the show.
As earnings season reaches the halfway mark, the focus is on whether profit growth is good enough to keep the market moving higher.
You'd think we'd get a pretty good lift from Apple and Facebook earnings as well as talk of more M&A activity, but it all faded.
Check out which companies are making headlines after the bell Thursday.
For years, Wall Street pros have been bemoaning the exodus of mom-and-pop investors. Recent data suggest the trend might be changing.
Some analysts say the market may be quietly sniffing out a higher rate of inflation.
Some of Thursday's midday movers:
A new survey shows that many on Wall Street agree with Michael Lewis that U.S. equity markets aren't fair.
Some of the names on the move ahead of the open.
New Zealand's central bank raised interest rates on Thursday and signaled that it would keep tightening monetary policy in the coming months.
The White House is weighing candidates with banking backgrounds to fill gaps on the Fed's depleted board, sources familiar with the matter said.
Apple in the news after the bell Wednesday:
Deutsche Bank is facing pressure from investors to raise capital amid fears the bank is not robust enough to face challenges, Financial Times reports.
Some of Wednesday's midday movers:
Bill Ackman tells CNBC that his losses from betting against Herbalife have been "more than cut in half" based on the recent downturn of the company's stock.
Maybe it was the martini that helped Carl Icahn publicly support longtime nemesis Bill Ackman, but he still calls Marty Lipton "dead wrong."
The Supreme Court is hearing an important case regarding TV streaming rights, but apparently its members haven't a clue as to how technology works.
Stocks of SunEdison and Conn's jumped Tuesday on news that David Einhorn's Greenlight Capital had opened new positions in them.
Happy Wednesday and welcome to the Morning Six-Pack, where we're always trying to beat analyst estimates and surprise to the upside.
Bill Ackman also tells CNBC that Allergan's poison-pill defense doesn't make his takeover bid more difficult.
Get the best of CNBC in your inbox